Advertisement

Index by author

March 01, 1982; Volume 21,Issue 2

A

  1. Aktories, K

    1. Stimulation of a low Km GTPase by inhibitors of adipocyte adenylate cyclase.
      K Aktories, G Schultz and K H Jakobs
      Molecular Pharmacology March 1982, 21 (2) 336-342;

  2. Albuquerque, E X

    1. Actions of the histrionicotoxins at the ion channel of the nicotinic acetylcholine receptor and at the voltage-sensitive ion channels of muscle membranes.
      C E Spivak, M A Maleque, A C Oliveira, L M Masukawa, T Tokuyama, J W Daly and E X Albuquerque
      Molecular Pharmacology March 1982, 21 (2) 351-361;

  3. Anderson, K S

    1. Conformational requirements of alpha 2-adrenergic receptors.
      R R Ruffolo, K S Anderson and D D Miller
      Molecular Pharmacology March 1982, 21 (2) 259-261;

B

  1. Baird, T M

    1. Cyclic AMP receptors and cation fluxes in the turkey erythrocyte.
      S A Rudolph, T M Baird and J W Wardell
      Molecular Pharmacology March 1982, 21 (2) 503-510;

  2. Bastow, K F

    1. Effect of methotrexate on dihydrofolate reductase activity in methotrexate-resistant human KB cells.
      B A Domin, S P Grill, K F Bastow and Y C Cheng
      Molecular Pharmacology March 1982, 21 (2) 478-482;

  3. Batardy-Grégoire, M

    1. Induction and modification of rat liver microsomal arylamide N-hydroxylase by various pretreatments.
      C Razzouk, M Batardy-Grégoire and M Roberfroid
      Molecular Pharmacology March 1982, 21 (2) 449-457;

  4. Ben-Baruch, G

    1. Cooperativity pattern in the interaction of the antiestrogen drug clomiphene with the Muscarinic receptors.
      G Ben-Baruch, G Schreiber and M Sokolovsky
      Molecular Pharmacology March 1982, 21 (2) 287-293;

  5. Bennett, L L

    1. In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells.
      W C Tseng, D Derse, Y C Cheng, R W Brockman and L L Bennett
      Molecular Pharmacology March 1982, 21 (2) 474-477;

  6. Borchardt, R T

    1. Characterization of serotonin uptake in cultured neuroblastoma cells. Difference between differentiated and nondifferentiated cells.
      J R Yoffe and R T Borchardt
      Molecular Pharmacology March 1982, 21 (2) 362-367;
    2. Characterization of serotonin uptake in cultured pheochromocytoma cells. Comparison with norepinephrine uptake.
      J R Yoffe and R T Borchardt
      Molecular Pharmacology March 1982, 21 (2) 368-373;

  7. Bornheim, L M

    1. Metabolic-intermediate complex formation reveals major changes in rat hepatic cytochrome P-450 subpopulations in addition to those forms previously purified after phenobarbital, beta-naphthoflavone, and isosafrole induction.
      L M Bornheim and M R Franklin
      Molecular Pharmacology March 1982, 21 (2) 527-532;

  8. Brockman, R W

    1. In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells.
      W C Tseng, D Derse, Y C Cheng, R W Brockman and L L Bennett
      Molecular Pharmacology March 1982, 21 (2) 474-477;

  9. Brufani, M

    1. Structure-activity relationships in the ansamycins. Molecular structure and activity of 3-carbomethoxy rifamycin S.
      M Brufani, L Cellai, S Cerrini, W Fedeli, A Segre and A Vaciago
      Molecular Pharmacology March 1982, 21 (2) 394-399;

C

  1. Carpy, A

    1. Comparison of crystallographic and quantum mechanical analysis with biological data on clonidine and some related analogues.
      A Carpy, J M Leger, G Leclerc, N Decker, B Rouot and C G Wermuth
      Molecular Pharmacology March 1982, 21 (2) 400-408;

  2. Cavagnaro, J

    1. Norcocaine nitroxide. A potential hepatotoxic metabolite of cocaine.
      E J Rauckman, G M Rosen and J Cavagnaro
      Molecular Pharmacology March 1982, 21 (2) 458-463;

  3. Cellai, L

    1. Structure-activity relationships in the ansamycins. Molecular structure and activity of 3-carbomethoxy rifamycin S.
      M Brufani, L Cellai, S Cerrini, W Fedeli, A Segre and A Vaciago
      Molecular Pharmacology March 1982, 21 (2) 394-399;

  4. Cerrini, S

    1. Structure-activity relationships in the ansamycins. Molecular structure and activity of 3-carbomethoxy rifamycin S.
      M Brufani, L Cellai, S Cerrini, W Fedeli, A Segre and A Vaciago
      Molecular Pharmacology March 1982, 21 (2) 394-399;

  5. Cheng, Y C

    1. In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells.
      W C Tseng, D Derse, Y C Cheng, R W Brockman and L L Bennett
      Molecular Pharmacology March 1982, 21 (2) 474-477;
    2. Effect of methotrexate on dihydrofolate reductase activity in methotrexate-resistant human KB cells.
      B A Domin, S P Grill, K F Bastow and Y C Cheng
      Molecular Pharmacology March 1982, 21 (2) 478-482;

  6. Cho, A K

    1. Chemical transformations of xylamine (N-2'-chloroethyl-N-ethyl-2-methylbenzylamine) in solution. Pharmacological activity of the species derived from this irreversible norepinephrine uptake inhibitor.
      R W Ransom, R C Kammerer and A K Cho
      Molecular Pharmacology March 1982, 21 (2) 380-386;

  7. Cooper, M J

    1. Guanine nucleotide and cation regulation of the binding of [3H]cyclohexyladenosine and [3H]diethylphenylxanthine to adenosine A1 receptors in brain membranes.
      R R Goodman, M J Cooper, M Gavish and S H Snyder
      Molecular Pharmacology March 1982, 21 (2) 329-335;

D

  1. Dahl, S G

    1. Chlorpromazine, methotrimeprazine, and metabolites. Structural changes accompanying the loss of neuroleptic potency by ring sulfoxidation.
      S G Dahl, M Hjorth and E Hough
      Molecular Pharmacology March 1982, 21 (2) 409-414;

  2. Daigneault, E A

    1. Differential stereoselectivity of methotrimeprazine enantiomers for selected central nervous system receptor types.
      T A Robert, A N Hagardorn and E A Daigneault
      Molecular Pharmacology March 1982, 21 (2) 315-319;

  3. Daly, J W

    1. Actions of the histrionicotoxins at the ion channel of the nicotinic acetylcholine receptor and at the voltage-sensitive ion channels of muscle membranes.
      C E Spivak, M A Maleque, A C Oliveira, L M Masukawa, T Tokuyama, J W Daly and E X Albuquerque
      Molecular Pharmacology March 1982, 21 (2) 351-361;

  4. Decker, N

    1. Comparison of crystallographic and quantum mechanical analysis with biological data on clonidine and some related analogues.
      A Carpy, J M Leger, G Leclerc, N Decker, B Rouot and C G Wermuth
      Molecular Pharmacology March 1982, 21 (2) 400-408;

  5. Derse, D

    1. In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells.
      W C Tseng, D Derse, Y C Cheng, R W Brockman and L L Bennett
      Molecular Pharmacology March 1982, 21 (2) 474-477;

  6. Domin, B A

    1. Effect of methotrexate on dihydrofolate reductase activity in methotrexate-resistant human KB cells.
      B A Domin, S P Grill, K F Bastow and Y C Cheng
      Molecular Pharmacology March 1982, 21 (2) 478-482;

  7. Duffel, M W

    1. Cysteine S-conjugate N-acetyltransferase from rat kidney microsomes.
      M W Duffel and W B Jakoby
      Molecular Pharmacology March 1982, 21 (2) 444-448;

E

  1. Eckhardt, S B

    1. A structure-activity study of the transport sites for the hypothalamic and striatal catecholamine uptake systems. Similarities and differences.
      S B Eckhardt, R A Maxwell and R M Ferris
      Molecular Pharmacology March 1982, 21 (2) 374-379;

F

  1. Fedeli, W

    1. Structure-activity relationships in the ansamycins. Molecular structure and activity of 3-carbomethoxy rifamycin S.
      M Brufani, L Cellai, S Cerrini, W Fedeli, A Segre and A Vaciago
      Molecular Pharmacology March 1982, 21 (2) 394-399;

  2. Fehske, K J

    1. Characterization of an important drug binding area on human serum albumin including the high-affinity binding sites of warfarin and azapropazone.
      K J Fehske, U Schläfer, U Wollert and W E Müller
      Molecular Pharmacology March 1982, 21 (2) 387-393;

  3. Feinstein, M B

    1. Effects of the calmodulin antagonist trifluoperazine on stimulus-induced calcium mobilization, aggregation, secretion, and protein phosphorylation in platelets.
      M B Feinstein and R A Hadjian
      Molecular Pharmacology March 1982, 21 (2) 422-431;

  4. Ferris, R M

    1. A structure-activity study of the transport sites for the hypothalamic and striatal catecholamine uptake systems. Similarities and differences.
      S B Eckhardt, R A Maxwell and R M Ferris
      Molecular Pharmacology March 1982, 21 (2) 374-379;

  5. Finkelstein, E

    1. Production of hydroxyl radical by decomposition of superoxide spin-trapped adducts.
      E Finkelstein, G M Rosen and E J Rauckman
      Molecular Pharmacology March 1982, 21 (2) 262-265;

  6. Franklin, M R

    1. Metabolic-intermediate complex formation reveals major changes in rat hepatic cytochrome P-450 subpopulations in addition to those forms previously purified after phenobarbital, beta-naphthoflavone, and isosafrole induction.
      L M Bornheim and M R Franklin
      Molecular Pharmacology March 1982, 21 (2) 527-532;

  7. Fyfe, J A

    1. Differential phosphorylation of (E)-5-(2-bromovinyl)-2'-deoxyuridine monophosphate by thymidylate kinases from herpes simplex viruses types 1 and 2 and varicella zoster virus.
      J A Fyfe
      Molecular Pharmacology March 1982, 21 (2) 432-437;

G

  1. Gainer, M W

    1. In vivo regulation of muscarinic cholinergic receptors in embryonic chick brain.
      M R Meyer, M W Gainer and N M Nathanson
      Molecular Pharmacology March 1982, 21 (2) 280-286;

  2. Gavish, M

    1. Guanine nucleotide and cation regulation of the binding of [3H]cyclohexyladenosine and [3H]diethylphenylxanthine to adenosine A1 receptors in brain membranes.
      R R Goodman, M J Cooper, M Gavish and S H Snyder
      Molecular Pharmacology March 1982, 21 (2) 329-335;

  3. Glazer, R I

    1. Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture.
      R I Glazer and L S Lloyd
      Molecular Pharmacology March 1982, 21 (2) 468-473;

  4. Gommeren, W

    1. In vitro and in vivo binding characteristics of a new long-acting histamine H1 antagonist, astemizole.
      P M Laduron, P F Janssen, W Gommeren and J E Leysen
      Molecular Pharmacology March 1982, 21 (2) 294-300;

  5. Gonzalez, F J

    1. Differential inducibility of nuclear envelope epoxide hydratase by trans-stilbene oxide and phenobarbital.
      F J Gonzalez and C B Kasper
      Molecular Pharmacology March 1982, 21 (2) 511-516;

  6. Goodman, R R

    1. Guanine nucleotide and cation regulation of the binding of [3H]cyclohexyladenosine and [3H]diethylphenylxanthine to adenosine A1 receptors in brain membranes.
      R R Goodman, M J Cooper, M Gavish and S H Snyder
      Molecular Pharmacology March 1982, 21 (2) 329-335;

  7. Grill, S P

    1. Effect of methotrexate on dihydrofolate reductase activity in methotrexate-resistant human KB cells.
      B A Domin, S P Grill, K F Bastow and Y C Cheng
      Molecular Pharmacology March 1982, 21 (2) 478-482;

H

  1. Hadjian, R A

    1. Effects of the calmodulin antagonist trifluoperazine on stimulus-induced calcium mobilization, aggregation, secretion, and protein phosphorylation in platelets.
      M B Feinstein and R A Hadjian
      Molecular Pharmacology March 1982, 21 (2) 422-431;

  2. Hagardorn, A N

    1. Differential stereoselectivity of methotrimeprazine enantiomers for selected central nervous system receptor types.
      T A Robert, A N Hagardorn and E A Daigneault
      Molecular Pharmacology March 1982, 21 (2) 315-319;

  3. Herz, A

    1. Potentiation of opiate action in neuroblastoma N18TG2 cells by lipid incorporation.
      P Y Law, T D Nicksic, M A O'Rourke, J E Koehler, A Herz and H H Loh
      Molecular Pharmacology March 1982, 21 (2) 492-502;
    2. Discrimination of three opiate receptor binding sites with the use of a computerized curve-fitting technique.
      A Pfeiffer and A Herz
      Molecular Pharmacology March 1982, 21 (2) 266-271;

  4. Hjorth, M

    1. Chlorpromazine, methotrimeprazine, and metabolites. Structural changes accompanying the loss of neuroleptic potency by ring sulfoxidation.
      S G Dahl, M Hjorth and E Hough
      Molecular Pharmacology March 1982, 21 (2) 409-414;

  5. Hough, E

    1. Chlorpromazine, methotrimeprazine, and metabolites. Structural changes accompanying the loss of neuroleptic potency by ring sulfoxidation.
      S G Dahl, M Hjorth and E Hough
      Molecular Pharmacology March 1982, 21 (2) 409-414;

J

  1. Jakobs, K H

    1. Stimulation of a low Km GTPase by inhibitors of adipocyte adenylate cyclase.
      K Aktories, G Schultz and K H Jakobs
      Molecular Pharmacology March 1982, 21 (2) 336-342;

  2. Jakoby, W B

    1. Cysteine S-conjugate N-acetyltransferase from rat kidney microsomes.
      M W Duffel and W B Jakoby
      Molecular Pharmacology March 1982, 21 (2) 444-448;

  3. Janssen, P F

    1. In vitro and in vivo binding characteristics of a new long-acting histamine H1 antagonist, astemizole.
      P M Laduron, P F Janssen, W Gommeren and J E Leysen
      Molecular Pharmacology March 1982, 21 (2) 294-300;

  4. Ji, S

    1. Rates of alcohol dehydrogenase-dependent ethanol metabolism in periportal and pericentral regions of the perfused rat liver.
      T Kashiwagi, S Ji, J J Lemasters and R G Thurman
      Molecular Pharmacology March 1982, 21 (2) 438-443;

K

  1. Kammerer, R C

    1. Chemical transformations of xylamine (N-2'-chloroethyl-N-ethyl-2-methylbenzylamine) in solution. Pharmacological activity of the species derived from this irreversible norepinephrine uptake inhibitor.
      R W Ransom, R C Kammerer and A K Cho
      Molecular Pharmacology March 1982, 21 (2) 380-386;

  2. Kashiwagi, T

    1. Rates of alcohol dehydrogenase-dependent ethanol metabolism in periportal and pericentral regions of the perfused rat liver.
      T Kashiwagi, S Ji, J J Lemasters and R G Thurman
      Molecular Pharmacology March 1982, 21 (2) 438-443;

  3. Kasper, C B

    1. Differential inducibility of nuclear envelope epoxide hydratase by trans-stilbene oxide and phenobarbital.
      F J Gonzalez and C B Kasper
      Molecular Pharmacology March 1982, 21 (2) 511-516;

  4. Klotz, A V

    1. Cytochrome P-450 and monooxygenase activity in cardiac microsomes from the fish Stenotomus chrysops.
      J J Stegeman, B R Woodin, A V Klotz, R E Wolke and N R Orme-Johnson
      Molecular Pharmacology March 1982, 21 (2) 517-526;

  5. Koehler, J E

    1. Comparison of opiate inhibition of adenylate cyclase activity in neuroblastoma N18tG2 and neuroblastoma x glioma NG108-15 hybrid cell lines.
      P Y Law, J E Koehler and H H Loh
      Molecular Pharmacology March 1982, 21 (2) 483-491;
    2. Potentiation of opiate action in neuroblastoma N18TG2 cells by lipid incorporation.
      P Y Law, T D Nicksic, M A O'Rourke, J E Koehler, A Herz and H H Loh
      Molecular Pharmacology March 1982, 21 (2) 492-502;

  6. Kurowski, M

    1. [3H]Etorphine receptor binding in vivo. Small fractional occupancy elicits analgesia.
      D C Perry, J S Rosenbaum, M Kurowski and W Sadée
      Molecular Pharmacology March 1982, 21 (2) 272-279;

L

  1. Laduron, P M

    1. In vitro and in vivo binding characteristics of a new long-acting histamine H1 antagonist, astemizole.
      P M Laduron, P F Janssen, W Gommeren and J E Leysen
      Molecular Pharmacology March 1982, 21 (2) 294-300;
    2. [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role.
      J E Leysen, C J Niemegeers, J M Van Nueten and P M Laduron
      Molecular Pharmacology March 1982, 21 (2) 301-314;

  2. Law, P Y

    1. Comparison of opiate inhibition of adenylate cyclase activity in neuroblastoma N18tG2 and neuroblastoma x glioma NG108-15 hybrid cell lines.
      P Y Law, J E Koehler and H H Loh
      Molecular Pharmacology March 1982, 21 (2) 483-491;
    2. Potentiation of opiate action in neuroblastoma N18TG2 cells by lipid incorporation.
      P Y Law, T D Nicksic, M A O'Rourke, J E Koehler, A Herz and H H Loh
      Molecular Pharmacology March 1982, 21 (2) 492-502;

  3. Leclerc, G

    1. Comparison of crystallographic and quantum mechanical analysis with biological data on clonidine and some related analogues.
      A Carpy, J M Leger, G Leclerc, N Decker, B Rouot and C G Wermuth
      Molecular Pharmacology March 1982, 21 (2) 400-408;

  4. Leeb-Lundberg, F

    1. Interactions of barbiturates of various pharmacological categories with benzodiazepine receptors.
      F Leeb-Lundberg and R W Olsen
      Molecular Pharmacology March 1982, 21 (2) 320-328;

  5. Leger, J M

    1. Comparison of crystallographic and quantum mechanical analysis with biological data on clonidine and some related analogues.
      A Carpy, J M Leger, G Leclerc, N Decker, B Rouot and C G Wermuth
      Molecular Pharmacology March 1982, 21 (2) 400-408;

  6. Lemasters, J J

    1. Rates of alcohol dehydrogenase-dependent ethanol metabolism in periportal and pericentral regions of the perfused rat liver.
      T Kashiwagi, S Ji, J J Lemasters and R G Thurman
      Molecular Pharmacology March 1982, 21 (2) 438-443;

  7. Leysen, J E

    1. In vitro and in vivo binding characteristics of a new long-acting histamine H1 antagonist, astemizole.
      P M Laduron, P F Janssen, W Gommeren and J E Leysen
      Molecular Pharmacology March 1982, 21 (2) 294-300;
    2. [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role.
      J E Leysen, C J Niemegeers, J M Van Nueten and P M Laduron
      Molecular Pharmacology March 1982, 21 (2) 301-314;

  8. Lloyd, L S

    1. Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture.
      R I Glazer and L S Lloyd
      Molecular Pharmacology March 1982, 21 (2) 468-473;

  9. Loh, H H

    1. Comparison of opiate inhibition of adenylate cyclase activity in neuroblastoma N18tG2 and neuroblastoma x glioma NG108-15 hybrid cell lines.
      P Y Law, J E Koehler and H H Loh
      Molecular Pharmacology March 1982, 21 (2) 483-491;
    2. Potentiation of opiate action in neuroblastoma N18TG2 cells by lipid incorporation.
      P Y Law, T D Nicksic, M A O'Rourke, J E Koehler, A Herz and H H Loh
      Molecular Pharmacology March 1982, 21 (2) 492-502;

M

  1. Maleque, M A

    1. Actions of the histrionicotoxins at the ion channel of the nicotinic acetylcholine receptor and at the voltage-sensitive ion channels of muscle membranes.
      C E Spivak, M A Maleque, A C Oliveira, L M Masukawa, T Tokuyama, J W Daly and E X Albuquerque
      Molecular Pharmacology March 1982, 21 (2) 351-361;

  2. Masukawa, L M

    1. Actions of the histrionicotoxins at the ion channel of the nicotinic acetylcholine receptor and at the voltage-sensitive ion channels of muscle membranes.
      C E Spivak, M A Maleque, A C Oliveira, L M Masukawa, T Tokuyama, J W Daly and E X Albuquerque
      Molecular Pharmacology March 1982, 21 (2) 351-361;

  3. Maxwell, R A

    1. A structure-activity study of the transport sites for the hypothalamic and striatal catecholamine uptake systems. Similarities and differences.
      S B Eckhardt, R A Maxwell and R M Ferris
      Molecular Pharmacology March 1982, 21 (2) 374-379;

  4. Meyer, M R

    1. In vivo regulation of muscarinic cholinergic receptors in embryonic chick brain.
      M R Meyer, M W Gainer and N M Nathanson
      Molecular Pharmacology March 1982, 21 (2) 280-286;

  5. Miller, D D

    1. Conformational requirements of alpha 2-adrenergic receptors.
      R R Ruffolo, K S Anderson and D D Miller
      Molecular Pharmacology March 1982, 21 (2) 259-261;

  6. Müller, W E

    1. Characterization of an important drug binding area on human serum albumin including the high-affinity binding sites of warfarin and azapropazone.
      K J Fehske, U Schläfer, U Wollert and W E Müller
      Molecular Pharmacology March 1982, 21 (2) 387-393;

N

  1. Nathanson, N M

    1. In vivo regulation of muscarinic cholinergic receptors in embryonic chick brain.
      M R Meyer, M W Gainer and N M Nathanson
      Molecular Pharmacology March 1982, 21 (2) 280-286;

  2. Neal, R A

    1. Inhibition of rat liver cytochrome P-450 by benzyl hydrodisulfide.
      T Sawahata and R A Neal
      Molecular Pharmacology March 1982, 21 (2) 464-467;

  3. Nicksic, T D

    1. Potentiation of opiate action in neuroblastoma N18TG2 cells by lipid incorporation.
      P Y Law, T D Nicksic, M A O'Rourke, J E Koehler, A Herz and H H Loh
      Molecular Pharmacology March 1982, 21 (2) 492-502;

  4. Niemegeers, C J

    1. [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role.
      J E Leysen, C J Niemegeers, J M Van Nueten and P M Laduron
      Molecular Pharmacology March 1982, 21 (2) 301-314;

O

  1. O'Rourke, M A

    1. Potentiation of opiate action in neuroblastoma N18TG2 cells by lipid incorporation.
      P Y Law, T D Nicksic, M A O'Rourke, J E Koehler, A Herz and H H Loh
      Molecular Pharmacology March 1982, 21 (2) 492-502;

  2. Oliveira, A C

    1. Actions of the histrionicotoxins at the ion channel of the nicotinic acetylcholine receptor and at the voltage-sensitive ion channels of muscle membranes.
      C E Spivak, M A Maleque, A C Oliveira, L M Masukawa, T Tokuyama, J W Daly and E X Albuquerque
      Molecular Pharmacology March 1982, 21 (2) 351-361;

  3. Olsen, R W

    1. Interactions of barbiturates of various pharmacological categories with benzodiazepine receptors.
      F Leeb-Lundberg and R W Olsen
      Molecular Pharmacology March 1982, 21 (2) 320-328;

  4. Orme-Johnson, N R

    1. Cytochrome P-450 and monooxygenase activity in cardiac microsomes from the fish Stenotomus chrysops.
      J J Stegeman, B R Woodin, A V Klotz, R E Wolke and N R Orme-Johnson
      Molecular Pharmacology March 1982, 21 (2) 517-526;

P

  1. Palatini, P

    1. Magnesium-dependent inhibition of beef heart soluble mitochondrial adenosine triphosphatase by tricyclic antipsychotics.
      P Palatini
      Molecular Pharmacology March 1982, 21 (2) 415-421;

  2. Perry, D C

    1. [3H]Etorphine receptor binding in vivo. Small fractional occupancy elicits analgesia.
      D C Perry, J S Rosenbaum, M Kurowski and W Sadée
      Molecular Pharmacology March 1982, 21 (2) 272-279;

  3. Pfeiffer, A

    1. Discrimination of three opiate receptor binding sites with the use of a computerized curve-fitting technique.
      A Pfeiffer and A Herz
      Molecular Pharmacology March 1982, 21 (2) 266-271;

R

  1. Ransom, R W

    1. Chemical transformations of xylamine (N-2'-chloroethyl-N-ethyl-2-methylbenzylamine) in solution. Pharmacological activity of the species derived from this irreversible norepinephrine uptake inhibitor.
      R W Ransom, R C Kammerer and A K Cho
      Molecular Pharmacology March 1982, 21 (2) 380-386;

  2. Rauckman, E J

    1. Norcocaine nitroxide. A potential hepatotoxic metabolite of cocaine.
      E J Rauckman, G M Rosen and J Cavagnaro
      Molecular Pharmacology March 1982, 21 (2) 458-463;
    2. Production of hydroxyl radical by decomposition of superoxide spin-trapped adducts.
      E Finkelstein, G M Rosen and E J Rauckman
      Molecular Pharmacology March 1982, 21 (2) 262-265;

  3. Razzouk, C

    1. Induction and modification of rat liver microsomal arylamide N-hydroxylase by various pretreatments.
      C Razzouk, M Batardy-Grégoire and M Roberfroid
      Molecular Pharmacology March 1982, 21 (2) 449-457;

  4. Roberfroid, M

    1. Induction and modification of rat liver microsomal arylamide N-hydroxylase by various pretreatments.
      C Razzouk, M Batardy-Grégoire and M Roberfroid
      Molecular Pharmacology March 1982, 21 (2) 449-457;

  5. Robert, T A

    1. Differential stereoselectivity of methotrimeprazine enantiomers for selected central nervous system receptor types.
      T A Robert, A N Hagardorn and E A Daigneault
      Molecular Pharmacology March 1982, 21 (2) 315-319;

  6. Rosen, G M

    1. Norcocaine nitroxide. A potential hepatotoxic metabolite of cocaine.
      E J Rauckman, G M Rosen and J Cavagnaro
      Molecular Pharmacology March 1982, 21 (2) 458-463;
    2. Production of hydroxyl radical by decomposition of superoxide spin-trapped adducts.
      E Finkelstein, G M Rosen and E J Rauckman
      Molecular Pharmacology March 1982, 21 (2) 262-265;

  7. Rosenbaum, J S

    1. [3H]Etorphine receptor binding in vivo. Small fractional occupancy elicits analgesia.
      D C Perry, J S Rosenbaum, M Kurowski and W Sadée
      Molecular Pharmacology March 1982, 21 (2) 272-279;

  8. Rouot, B

    1. Comparison of crystallographic and quantum mechanical analysis with biological data on clonidine and some related analogues.
      A Carpy, J M Leger, G Leclerc, N Decker, B Rouot and C G Wermuth
      Molecular Pharmacology March 1982, 21 (2) 400-408;

  9. Rudolph, S A

    1. Cyclic AMP receptors and cation fluxes in the turkey erythrocyte.
      S A Rudolph, T M Baird and J W Wardell
      Molecular Pharmacology March 1982, 21 (2) 503-510;

  10. Ruffolo, R R

    1. Conformational requirements of alpha 2-adrenergic receptors.
      R R Ruffolo, K S Anderson and D D Miller
      Molecular Pharmacology March 1982, 21 (2) 259-261;

S

  1. Sadée, W

    1. [3H]Etorphine receptor binding in vivo. Small fractional occupancy elicits analgesia.
      D C Perry, J S Rosenbaum, M Kurowski and W Sadée
      Molecular Pharmacology March 1982, 21 (2) 272-279;

  2. Sawahata, T

    1. Inhibition of rat liver cytochrome P-450 by benzyl hydrodisulfide.
      T Sawahata and R A Neal
      Molecular Pharmacology March 1982, 21 (2) 464-467;

  3. Schläfer, U

    1. Characterization of an important drug binding area on human serum albumin including the high-affinity binding sites of warfarin and azapropazone.
      K J Fehske, U Schläfer, U Wollert and W E Müller
      Molecular Pharmacology March 1982, 21 (2) 387-393;

  4. Schreiber, G

    1. Cooperativity pattern in the interaction of the antiestrogen drug clomiphene with the Muscarinic receptors.
      G Ben-Baruch, G Schreiber and M Sokolovsky
      Molecular Pharmacology March 1982, 21 (2) 287-293;

  5. Schultz, G

    1. Stimulation of a low Km GTPase by inhibitors of adipocyte adenylate cyclase.
      K Aktories, G Schultz and K H Jakobs
      Molecular Pharmacology March 1982, 21 (2) 336-342;

  6. Segre, A

    1. Structure-activity relationships in the ansamycins. Molecular structure and activity of 3-carbomethoxy rifamycin S.
      M Brufani, L Cellai, S Cerrini, W Fedeli, A Segre and A Vaciago
      Molecular Pharmacology March 1982, 21 (2) 394-399;

  7. Snyder, S H

    1. Guanine nucleotide and cation regulation of the binding of [3H]cyclohexyladenosine and [3H]diethylphenylxanthine to adenosine A1 receptors in brain membranes.
      R R Goodman, M J Cooper, M Gavish and S H Snyder
      Molecular Pharmacology March 1982, 21 (2) 329-335;

  8. Sokolovsky, M

    1. Cooperativity pattern in the interaction of the antiestrogen drug clomiphene with the Muscarinic receptors.
      G Ben-Baruch, G Schreiber and M Sokolovsky
      Molecular Pharmacology March 1982, 21 (2) 287-293;

  9. Spivak, C E

    1. Actions of the histrionicotoxins at the ion channel of the nicotinic acetylcholine receptor and at the voltage-sensitive ion channels of muscle membranes.
      C E Spivak, M A Maleque, A C Oliveira, L M Masukawa, T Tokuyama, J W Daly and E X Albuquerque
      Molecular Pharmacology March 1982, 21 (2) 351-361;

  10. Stegeman, J J

    1. Cytochrome P-450 and monooxygenase activity in cardiac microsomes from the fish Stenotomus chrysops.
      J J Stegeman, B R Woodin, A V Klotz, R E Wolke and N R Orme-Johnson
      Molecular Pharmacology March 1982, 21 (2) 517-526;

  11. Strichartz, G

    1. Structure of the saxitoxin binding site at sodium channels in nerve membranes. Exchange of tritium from bound toxin molecules.
      G Strichartz
      Molecular Pharmacology March 1982, 21 (2) 343-350;

T

  1. Thurman, R G

    1. Rates of alcohol dehydrogenase-dependent ethanol metabolism in periportal and pericentral regions of the perfused rat liver.
      T Kashiwagi, S Ji, J J Lemasters and R G Thurman
      Molecular Pharmacology March 1982, 21 (2) 438-443;

  2. Tokuyama, T

    1. Actions of the histrionicotoxins at the ion channel of the nicotinic acetylcholine receptor and at the voltage-sensitive ion channels of muscle membranes.
      C E Spivak, M A Maleque, A C Oliveira, L M Masukawa, T Tokuyama, J W Daly and E X Albuquerque
      Molecular Pharmacology March 1982, 21 (2) 351-361;

  3. Tseng, W C

    1. In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells.
      W C Tseng, D Derse, Y C Cheng, R W Brockman and L L Bennett
      Molecular Pharmacology March 1982, 21 (2) 474-477;

V

  1. Vaciago, A

    1. Structure-activity relationships in the ansamycins. Molecular structure and activity of 3-carbomethoxy rifamycin S.
      M Brufani, L Cellai, S Cerrini, W Fedeli, A Segre and A Vaciago
      Molecular Pharmacology March 1982, 21 (2) 394-399;

  2. Van Nueten, J M

    1. [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role.
      J E Leysen, C J Niemegeers, J M Van Nueten and P M Laduron
      Molecular Pharmacology March 1982, 21 (2) 301-314;

W

  1. Wardell, J W

    1. Cyclic AMP receptors and cation fluxes in the turkey erythrocyte.
      S A Rudolph, T M Baird and J W Wardell
      Molecular Pharmacology March 1982, 21 (2) 503-510;

  2. Wermuth, C G

    1. Comparison of crystallographic and quantum mechanical analysis with biological data on clonidine and some related analogues.
      A Carpy, J M Leger, G Leclerc, N Decker, B Rouot and C G Wermuth
      Molecular Pharmacology March 1982, 21 (2) 400-408;

  3. Wolke, R E

    1. Cytochrome P-450 and monooxygenase activity in cardiac microsomes from the fish Stenotomus chrysops.
      J J Stegeman, B R Woodin, A V Klotz, R E Wolke and N R Orme-Johnson
      Molecular Pharmacology March 1982, 21 (2) 517-526;

  4. Wollert, U

    1. Characterization of an important drug binding area on human serum albumin including the high-affinity binding sites of warfarin and azapropazone.
      K J Fehske, U Schläfer, U Wollert and W E Müller
      Molecular Pharmacology March 1982, 21 (2) 387-393;

  5. Woodin, B R

    1. Cytochrome P-450 and monooxygenase activity in cardiac microsomes from the fish Stenotomus chrysops.
      J J Stegeman, B R Woodin, A V Klotz, R E Wolke and N R Orme-Johnson
      Molecular Pharmacology March 1982, 21 (2) 517-526;

Y

  1. Yoffe, J R

    1. Characterization of serotonin uptake in cultured neuroblastoma cells. Difference between differentiated and nondifferentiated cells.
      J R Yoffe and R T Borchardt
      Molecular Pharmacology March 1982, 21 (2) 362-367;
    2. Characterization of serotonin uptake in cultured pheochromocytoma cells. Comparison with norepinephrine uptake.
      J R Yoffe and R T Borchardt
      Molecular Pharmacology March 1982, 21 (2) 368-373;
Back to top

In this issue

Advertisement